中国肺癌杂志2025，Vol.28Issue(6)：450-459,10.DOI:10.3779/j.issn.1009-3419.2025.106.12
布格替尼治疗非小细胞肺癌的研究新进展
Recent Advances in the Treatment of Non-small Cell Lung Cancer with Brigatinib
郁佳 1任胜祥1
作者信息
- 1. 200082 上海,同济大学附属上海市肺科医院肿瘤科
- 折叠
摘要
Abstract
The discovery of anaplastic lymphoma kinase(ALK)tyrosine kinase gene rearrangement mutations in non-small cell lung cancer(NSCLC)has driven continuous advancements in ALK-targeted therapies.The next generation of ALK tyrosine kinase inhibitor,Brigatinib,has demonstrated significant efficacy in patients with ALK-positive NSCLC,offering clinical benefits in deep response of tumor,treatment of brain metastases patients,quality of life,and long-term survival.This review will provide current advancements and exploratory directions for Brigatinib.关键词
肺肿瘤/非小细胞肺癌/间变性淋巴瘤激酶酪氨酸激酶抑制剂/布格替尼/疗效/安全性Key words
Lung neoplasms/Non-small cell lung cancer/Anaplastic lymphoma kinase-tyrosine kinase inhibitors/Brigatinib/Efficacy/Safety引用本文复制引用
郁佳,任胜祥..布格替尼治疗非小细胞肺癌的研究新进展[J].中国肺癌杂志,2025,28(6):450-459,10.
